公开(公告)号：US20170224795A1

公开(公告)日：2017-08-10

申请号：US15411115

申请日：2017-01-20

Applicant: OncoTherapy Science, Inc.

Inventor： YASUHARU NISHIMURA ,  YUSUKE TOMITA ,  RYUJI OSAWA

IPC: A61K39/00 ,  C12N5/0783 ,  C12N5/078 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5154 ,  A61K2039/57 ,  A61K2039/70 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/76 ,  C12N5/0634 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C12N2501/405 ,  C12N2502/11

Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

公开(公告)号：US20180079791A1

公开(公告)日：2018-03-22

申请号：US15500906

申请日：2015-07-31

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： TAKUYA TSUNODA ,  RYUJI OSAWA ,  SACHIKO YAMASHITA ,  TOMOHISA WATANABE

IPC: C07K14/47 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00 ,  G01N33/50

Abstract: The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20180042954A1

公开(公告)日：2018-02-15

申请号：US15500895

申请日：2015-07-31

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： TAKUYA TSUNODA ,  RYUJI OSAWA ,  SACHIKO YAMASHITA ,  TOMOHISA WATANABE ,  TETSURO HIKICHI

IPC: A61K31/7088 ,  C07K7/08 ,  G01N33/50 ,  C12Q1/02 ,  G01N33/15 ,  C07K7/06 ,  C12N15/09

Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20180117135A9

公开(公告)日：2018-05-03

申请号：US15411115

申请日：2017-01-20

Applicant: OncoTherapy Science, Inc.

Inventor： YASUHARU NISHIMURA ,  YUSUKE TOMITA ,  RYUJI OSAWA

IPC: A61K39/00 ,  C07K14/47 ,  C12N5/0783 ,  C12N5/078

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5154 ,  A61K2039/57 ,  A61K2039/70 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/47 ,  C07K14/4702 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/76 ,  C12N5/0634 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C12N2501/405 ,  C12N2502/11

Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

公开(公告)号：US20170362287A1

公开(公告)日：2017-12-21

申请号：US15534311

申请日：2015-12-04

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： YASUHARU NISHIMURA ,  YUSUKE TOMITA ,  RYUJI OSAWA

IPC: C07K14/47 ,  G01N33/574 ,  C12N15/09 ,  A61K31/7088 ,  G01N33/68 ,  C07K7/06 ,  C12Q1/68 ,  C07K16/18 ,  A61K48/00

CPC classification number: C07K14/4725 ,  A61K31/7088 ,  A61K39/0011 ,  A61K48/00 ,  C07K7/06 ,  C07K14/47 ,  C07K16/18 ,  C12N15/09 ,  C12N2510/00 ,  C12Q1/68 ,  G01N33/574 ,  G01N33/57492 ,  G01N33/68

Abstract: Isolated GPC3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce GPC3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, hepatocellular carcinoma and melanoma.

公开(公告)号：US20180360938A1

公开(公告)日：2018-12-20

申请号：US16120102

申请日：2018-08-31

Applicant: OncoTherapy Science, Inc.

Inventor： TAKUYA TSUNODA ,  RYUJI OSAWA ,  SACHIKO YOSHIMURA ,  TOMOHISA WATANABE

IPC: A61K39/00 ,  G01N33/574 ,  A61K31/7088 ,  C07K16/40 ,  C12N9/00

Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

公开(公告)号：US20170333476A1

公开(公告)日：2017-11-23

申请号：US15501125

申请日：2015-07-31

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya TSUNODA ,  RYUJI OSAWA ,  SACHIKO YAMASHITA ,  TOMOHISA WATANABE ,  TETSURO HIKICHI

IPC: A61K35/14 ,  C12N5/10 ,  C07K7/08 ,  C07K7/06 ,  C12N15/09 ,  C07K16/18 ,  A61K39/00 ,  A61K48/00

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.